B. Metzler seel. Sohn & Co. Holding AG Acquires New Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,343 shares of the medical equipment provider's stock, valued at approximately $4,571,000.

A number of other large investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in Zimmer Biomet by 12.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares during the period. American Century Companies Inc. boosted its position in shares of Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after acquiring an additional 722,041 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after purchasing an additional 411,163 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after purchasing an additional 211,637 shares during the last quarter. Finally, Boston Partners raised its stake in Zimmer Biomet by 26.3% in the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock valued at $437,413,000 after purchasing an additional 691,191 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZBH. Wells Fargo & Company increased their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Robert W. Baird reduced their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Finally, Wolfe Research initiated coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a "peer perform" rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $123.22.

Zimmer Biomet Trading Down 1.5 %

Shares of Zimmer Biomet stock traded down $1.64 during midday trading on Wednesday, reaching $109.31. 1,476,375 shares of the company's stock traded hands, compared to its average volume of 1,497,754. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The stock has a 50 day moving average of $106.65 and a 200-day moving average of $109.86. The company has a market cap of $21.76 billion, a PE ratio of 20.78, a price-to-earnings-growth ratio of 2.08 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts' consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm posted $1.65 EPS. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.